Delta-Fly Pharma, Inc.
Stock Price Chart
2026/08/24 UpdatedPrice Trend
2026/08/24 UpdatedPrice & Trading Details
2026/08/24 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedNo financial data available
Latest IR Information
-
Notice Regarding Completion of Acquisition and Cancellation of the 9th and 11th Stock Acquisition Rights with Exercise Price Adjustment Clauses Due to Third-Party Allotments (Progress of Disclosure Items)
Read more -
Notice Regarding the Completion of Payments for the Third Unsecured Bond (Private Placement Bond) Issue
Read more -
Notice of Issuance of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause) and the 3rd Unsecured Bond (Private Placement), and Conclusion of Stock Acquisition Rights Purchase Agreement
Read more -
Notice Regarding the Issuance of the 12th Stock Acquisition Rights (with Exercise Price Revision Clause) via Third-Party Allotment, the 3rd Unsecured Bond (Private Placement), and the Conclusion of the Stock Acquisition Rights Purchase Agreement
Read more -
Notice Concerning the Issuance of the 12th Stock Acquisition Rights with an Exercise Price Adjustment Clause via Third-Party Allotment, the 3rd Unsecured Bonds (Private Placement Bonds), and the Conclusion of a Stock Acquisition Rights Purchase Agreement
Read more
Latest News (5 items)
Company Information
About
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
